BR112022003814A2 - Compositions and methods for treating viral infections - Google Patents

Compositions and methods for treating viral infections

Info

Publication number
BR112022003814A2
BR112022003814A2 BR112022003814A BR112022003814A BR112022003814A2 BR 112022003814 A2 BR112022003814 A2 BR 112022003814A2 BR 112022003814 A BR112022003814 A BR 112022003814A BR 112022003814 A BR112022003814 A BR 112022003814A BR 112022003814 A2 BR112022003814 A2 BR 112022003814A2
Authority
BR
Brazil
Prior art keywords
methods
viral infections
compositions
treating viral
viral
Prior art date
Application number
BR112022003814A
Other languages
Portuguese (pt)
Inventor
Serhat Gumrucku
Original Assignee
G Tech Bio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Tech Bio Llc filed Critical G Tech Bio Llc
Publication of BR112022003814A2 publication Critical patent/BR112022003814A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22062—Caspase-9 (3.4.22.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

composições e métodos para tratar infecções virais. a presente invenção fornece métodos e composições que usam constructos de ácidos nucleicos recombinantes ou uma partícula similar a vírus incompetente para replicação que codifica uma quimiocina, citocina ou proteína indutora de apoptose (por exemplo, caspase 9 (casp9)), ou outras toxinas em uma forma que só pode ser transcrita na presença de uma polimerase viral. estes métodos podem ser adaptados para atingir muitas infecções virais e reduzir ou eliminar a carga viral e fornecer um tratamento fundamentalmente diferente para infecções virais.compositions and methods for treating viral infections. The present invention provides methods and compositions that use recombinant nucleic acid constructs or a replication-incompetent virus-like particle encoding a chemokine, cytokine, or apoptosis-inducing protein (e.g., caspase 9 (casp9)), or other toxins in a form that can only be transcribed in the presence of a viral polymerase. these methods can be adapted to target many viral infections and reduce or eliminate viral load and provide a fundamentally different treatment for viral infections.

BR112022003814A 2019-08-29 2020-08-28 Compositions and methods for treating viral infections BR112022003814A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893460P 2019-08-29 2019-08-29
US202062968387P 2020-01-31 2020-01-31
US202062976491P 2020-02-14 2020-02-14
US202062985597P 2020-03-05 2020-03-05
PCT/US2020/048370 WO2021041787A1 (en) 2019-08-29 2020-08-28 Compositions and methods for treating viral infections

Publications (1)

Publication Number Publication Date
BR112022003814A2 true BR112022003814A2 (en) 2022-05-24

Family

ID=74686046

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003814A BR112022003814A2 (en) 2019-08-29 2020-08-28 Compositions and methods for treating viral infections

Country Status (11)

Country Link
EP (1) EP4022072A4 (en)
JP (1) JP2022546402A (en)
KR (1) KR20220095183A (en)
CN (1) CN114761566A (en)
AU (1) AU2020335886A1 (en)
BR (1) BR112022003814A2 (en)
CA (1) CA3149041A1 (en)
IL (1) IL290826A (en)
MX (1) MX2022002211A (en)
WO (1) WO2021041787A1 (en)
ZA (1) ZA202202370B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192086A1 (en) * 2021-03-06 2022-09-15 Gumrukcu Serhat Compositions and methods for treating and preventing coronavirus infections
WO2023220086A1 (en) * 2022-05-13 2023-11-16 Suntec Medical, Inc. Method for treating infectious disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001760B2 (en) * 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
JP6543338B2 (en) * 2014-06-20 2019-07-10 ドレクセル ユニバーシティ Tagged hepadnavirus e antigen and its use in screening of antiviral agents

Also Published As

Publication number Publication date
CA3149041A1 (en) 2021-03-04
CN114761566A (en) 2022-07-15
JP2022546402A (en) 2022-11-04
MX2022002211A (en) 2022-05-24
EP4022072A4 (en) 2023-09-06
IL290826A (en) 2022-04-01
ZA202202370B (en) 2022-11-30
AU2020335886A1 (en) 2022-03-17
EP4022072A1 (en) 2022-07-06
KR20220095183A (en) 2022-07-06
WO2021041787A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2018014573A (en) Zika virus vaccine.
BR112022003814A2 (en) Compositions and methods for treating viral infections
PH12019500596A1 (en) Recombinant binding proteins and their use
PH12017501792A1 (en) Recombinant binding proteins and their use
BR112014017384A2 (en) nucleic acid comprising or encoding a histone loop rod structure and a poly (a) sequence or polyadenylation signal to increase expression of a coded tumor antigen
EA201792501A1 (en) VACCINES FOR THE TREATMENT AND PREVENTION OF CANCER
MX2022013945A (en) Novel ankyrin repeat binding proteins and their uses.
BR112017018368A2 (en) rna-containing compositions for the treatment of tumoral diseases
PE20221259A1 (en) USE OF THE FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT AGAINST TUMORS WITH NRAS MUTATION
MX2022007122A (en) Designed ankyrin repeat domains with altered surface residues.
BR112022007677A2 (en) RECOMBINANT L-ASPARAGINASE
MX2021005345A (en) Compositions and methods.
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
BR112018075440A2 (en) compositions and methods for preventing and treating Zika virus infection
BR112021015751A2 (en) Gene therapy vectors for the treatment of danon's disease
MX2015013232A (en) Flavivirus neutralizing antibodies and methods of use thereof.
MX2021013491A (en) Novel gardnerella endolysins and uses thereof.
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
MX2021011181A (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease.
BR112020004935A2 (en) Pharmaceutical composition comprising an antibody which specifically binds to the n-terminus of lysyl-tRNA synthetase as an active ingredient for the prevention or treatment of cell migration-related disease
PH12018500058A1 (en) Fusion molecules
CL2020001884A1 (en) Human Antibodies to Influenza Hemagglutinin.
MX2021005751A (en) Antibodies to mucin-16 and methods of use thereof.
MX2020007050A (en) A combination of plasma immunoglobulin and antigen- specific immunoglobulin for the modification of the immune system and the treatment or prevention of allergic diseases.